Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.66 and traded as high as $1.74. Nabriva Therapeutics shares last traded at $1.65, with a volume of 5,391 shares changing hands.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on shares of Nabriva Therapeutics in a report on Thursday. They set a “hold” rating on the stock.
Nabriva Therapeutics Trading Down 3.1 %
The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.78. The stock’s fifty day moving average is $1.66 and its two-hundred day moving average is $1.78.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Nabriva Therapeutics stock. Susquehanna International Group LLP purchased a new position in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 22,294 shares of the biotechnology company’s stock, valued at approximately $41,000. Susquehanna International Group LLP owned about 0.07% of Nabriva Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 0.23% of the company’s stock.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.